Search results for: Multi-Indication Medicines

Dilek Sernur Eminoğulları

26 January 2024

…Her main interest areas include health technology assessment models, rare disease policies, innovative contracting models, the use of real world data in reimbursement, patient access to medicines, e-health and vaccination…

Prof. John Cairns

8 March 2024

…since 2020. He has previously been a member of the NIE technology appraisal committee, as well as the Scottish Medicines Consortium. He is currently a member of the NIHR advanced…

Drug Shortages: What are the causes, consequences and pathways to a solution?

24 September 2024, 3:00pm

Across the globe, drug shortages are becoming increasingly common across a range of therapeutic areas. Earlier this year, OHE published a report looking at the Dynamics of Drug Shortages, and…

Chittawan Poonsiri

4 September 2024

…Her past research includes economic evaluations of medicines and medical devices to inform policy decisions in Thailand. She is now focused on research related to health equity, antimicrobial resistance, cancer,…

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

10 March 2025

…to be updated to reflect the proposal. This consulting report, Challenges and Solutions for Budget Impact Analysis of Gene Therapies, was commissioned and funded by Johnson & Johnson Innovative Medicines…

Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order

2 June 2025

…in purchasing medicines, in contrast to the greater reliance on the private market seen in the U.S.” How is this Executive Order different to the previous one in 2020? The…

OHE Graduate School

…career. Even if you don’t have a background in economics, if you’re interested in how healthcare is financed and delivered, how medicines are developed and the effects and benefits of…

Climate action is health action: OHE’s focus on sustainability

22 July 2025

…the UK will need to be replicated internationally to have any impact. Meaningful engagement, collaboration and action need to be taken now by governments, health systems, medicines regulators and companies…

Brendan Shaw

22 June 2026

…pharmaceutical industry. Prior to this he was Chief Executive and head of health policy at Medicines Australia, the association for the Australian innovative pharmaceutical industry. Brendan has also served as…